Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.41 |
| ▸ | NOS3 | P29474 | 5/20 | 0.41 |
| ▸ | NOS2 | P35228 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9615916 | 0.75 | NOS1 (0.40) | NOS1NOS3NOS2ALDH1A1MAPT | |
| SCHEMBL9559207 | 0.69 | NOS1 (0.47) | NOS1NOS3NOS2ALDH1A1 | |
| SCHEMBL3846230 | 0.69 | NOS1 (0.41) | NOS1NOS3NOS2ALDH1A1MAPT | |
| SCHEMBL6170685 | 0.69 | NOS1 (0.49) | NOS1NOS3NOS2ANPEP | |
| SCHEMBL145755 | 0.68 | NOS1 (0.50) | NOS1NOS3NOS2ALDH1A1 | |
| SCHEMBL30074503 | 0.68 | NOS1 (0.50) | NOS1NOS3NOS2ALDH1A1 | |
| SCHEMBL10736168 | 0.67 | TP53 (0.47) | POLBALDH1A1MAPTGAA | |
| SCHEMBL7213386 | 0.66 | MAPT (0.50) | ALDH1A1MAPTLMNAGAAL3MBTL1 | |
| SCHEMBL19279335 | 0.66 | NOS1 (0.38) | NOS1NOS3NOS2 | |
| SCHEMBL11033988 | 0.66 | ALDH1A1 (0.56) | POLBALDH1A1MAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820845-B1 | NOVEL, NEW GENERATION INHIBITOR COMPOUNDS SPECIFIC TO GST P1 ENZYME | HACETTEPE UENIVERSITESI (TR) | 2023-05-24 | — | — | EP | disclosed |
| US-20220074941-A1 | HSP90 COMBINATION THERAPY | SLOAN KETTERING INST CANCER RES (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3820845-A1 | NOVEL, NEW GENERATION INHIBITOR COMPOUNDS SPECIFIC TO GST P1 ENZYME | HACETTEPE ÜNIVERSITESI (TR) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020130974-A1 | NOVEL, NEW GENERATION INHIBITOR COMPOUNDS SPECIFIC TO GST P1 ENZYME | HACETTEPE ÜNİVERSİTESİ (TR) | 2020-06-25 | — | — | WO | disclosed |
| US-20140315929-A1 | HSP90 COMBINATION THERAPY | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2701747-A2 | HSP90 COMBINATION THERAPY | Sloan-Kettering Institute for Cancer Research (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149493-A2 | HSP90 COMBINATION THERAPY | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-11-01 | — | — | WO | disclosed |
| CN-102464604-A | Production method of N-methyl tetrahydrocarbazolone | UNIV HARBIN SCIENCE & TECH | 2012-05-23 | — | — | CN | disclosed |
| US-20070197797-A1 | Compounds and methods for carbazole synthesis | ROCHE COLORADO CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007077111-A1 | COMPOUNDS AND METHODS FOR CARBAZOLE SYNTHESIS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| EP-1499623-B1 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-¬(2-METHYL-1H-IMIDAZOL-1-YL)METHYL|-4H-CARBAZOL-4-ONE | TEVA GYOGYSZERGYAR ZARTKOERUEE (HU) | 2007-06-13 | — | — | EP | disclosed |
| US-20060252942-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | MOLNAR SANDOR | 2006-11-09 | — | — | US | disclosed |
| US-7098345-B2 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság (HU) | 2006-08-29 | — | — | US | disclosed |
| US-20050020655-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2005-01-27 | — | — | US | disclosed |
| EP-1499623-A1 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-[(2-METHYL-1H-IMIDAZOL-1-YL)METHYL]-4H-CARBAZOL-4-ONE | BIOGAL GYOGYSZERGYAR RT. (HU) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003093281-A1 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-[(2-METHYL-1H-IMIDAZOL-1-YL)METHYL]-4H-CARBAZOL-4-ONE | BIOGAL GYOGYSZERGYAR RT. (HU) | 2003-11-13 | — | — | WO | disclosed |
| US-6506901-B2 | 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma | WYETH | 2003-01-14 | — | — | US | disclosed |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006255-A2 | HYDROXY-(PIPERIDIN-4-YL-METHYLAMINO)-ALKYL BETA-3 ADRENERGIC RECEPTOR ANTAGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| US-5030646-A | Treatment of diseases resulting from disfunction of seretoninergic system | ADIR ET COMPAGNIE (FR) | 1991-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020655-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | CYP3A4, HTR4, TPH1 | NOS1 758/4885NOS3 583/4885NOS2 666/4885 |
| US-20060252942-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | SI, CYP3A4, CYP2C19 | NOS1 928/4885NOS3 633/4885NOS2 845/4885 |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB2 | NOS1 760/4885NOS3 486/4885NOS2 662/4885 |
| US-20220074941-A1 | HSP90 COMBINATION THERAPY | HSP90AB1, HSP90AB2P, HSP90B1 | NOS1 4455/4885NOS3 4522/4885NOS2 4351/4885 |
| US-20140315929-A1 | HSP90 COMBINATION THERAPY | HSP90AB1, HSP90AB2P, HSP90B1 | NOS1 4466/4885NOS3 4525/4885NOS2 4355/4885 |
| US-20070197797-A1 | Compounds and methods for carbazole synthesis | CNR2, CNR1, CYP2J2 | NOS1 2062/4885NOS3 1082/4885NOS2 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.